Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


September 02, 2015 2:33 AM ET

Biotechnology

Company Overview of Five Prime Therapeutics, Inc.

Company Overview

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes. The company’s product candidates include FPA008, an antibody that inhibits colony stimulating factor-1 receptor and is in Phase Ib clinical trials for the treatment of rheumatoid arthritis; and in pre-IND stage for pigmented villonodular synovitis and multiple cancers in combination with nivolumab. Its product candidates also comprise FPA144, an antibody that inhibits fibroblast growth factor receptor 2b and is in Phase I clinical trials to treat patients with gastric cancer; and FP-1039/GSK3052230, a fus...

Two Corporate Drive

South San Francisco, CA 94080

United States

Founded in 2001

123 Employees

Phone:

415-365-5600

Fax:

415-365-5601

Key Executives for Five Prime Therapeutics, Inc.

Founder, Chief Executive Officer, President and Director
Age: 66
Total Annual Compensation: $525.0K
Chief Medical Officer and Executive Vice President
Age: 57
Total Annual Compensation: $382.1K
Chief Business Officer, Executive Vice President and Director
Age: 46
Total Annual Compensation: $364.0K
Compensation as of Fiscal Year 2014.

Five Prime Therapeutics, Inc. Key Developments

Five Prime Therapeutics and Partner GlaxoSmithKline Reports Initial Data from Phase 1b Trial of Lung Cancer Treatment

Five Prime Therapeutics and partner GlaxoSmithKline reported results from the ongoing Phase 1b trial of FP-1039/GSK3052230 in patients with squamous non small cell lung cancer and mesothelioma. The Phase 1B trial being conducted by GlaxoSmithKline is evaluating the safety and efficacy of FP-1039/GSK3052230 weekly infusion in combination with paclitaxel + carboplatin in previously untreated FGFR1 gene amplified metastatic squamous NSCLC (Arm A). It is also evaluating it in combination with docetaxel in FGFR1 gene amplified metastatic squamous NSCLC that has progressed after at least 1 line of chemotherapy (Arm B) and finally in combination with pemetrexed + cisplatin in patients with untreated and unresectable malignant pleural mesothelioma (Arm C). GlaxoSmithKline continues to enroll patients in the study. Arm A and Arm C have advanced into the expansion phase and dose escalation is ongoing for Arm B. Five Prime licensed development and commercialization rights for FP-1039/GSK3052230 in the U.S., Europe and Canada to GSK, which funds clinical development. Five Prime retains rights outside of these regions as well as an option to co-promote FP-1039/GSK3052230 in the U.S.

Five Prime Therapeutics, Inc. Announces Board Changes

On August 20, 2015, the Board of Directors of the Five Prime Therapeutics, Inc. approved a change in title for Julia Hambleton and Aron Knickerbocker, with all such changes becoming effective immediately. The new titles of the two Named Officers are identified in the table below: Julie Hambleton Executive Vice President and Chief Medical Officer, Aron M. Knickerbocker Executive Vice President and Chief Business Officer.

Five Prime Therapeutics, Inc. Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Financial Guidance for the Full Year 2015

Five Prime Therapeutics, Inc. reported financial results for the second quarter and six months ended June 30, 2015. Net loss for the second quarter of 2015 was $11.5 million, or $0.45 per basic and diluted share, compared with a net loss of $9.9 million, or $0.46 per basic and diluted share, for the second quarter of 2014. This increase in net loss was primarily related to advancing the FPA008 development program into additional indications and expanding internal immuno-oncology research and preclinical activities. Collaboration and license revenue was $6.3 million against $5.0 million a year ago, primarily due to the $1.5 million upfront license payment from bluebird bio. For the six months, the company reported net loss of $22.5 million or $0.89 per basic and diluted share against $18.5 million or $0.92 per basic and diluted share a year ago. Collaboration and license revenue was $10.6 million against $8.5 million a year ago. The company expects full-year 2015 net cash used in operating activities to be between $65 and $70 million and estimates ending 2015 with between $158 and $163 million in cash, cash equivalents and marketable securities.

Similar Private Companies By Industry

Company Name Region
Ionian Technologies, Inc. United States
ZyStor Therapeutics, Inc. United States
Precision BioSciences, Inc. United States
Navitor Pharmaceuticals, Inc. United States
Phage Biotechnology Corporation United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Five Prime Therapeutics, Inc., please visit www.fiveprime.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.